High prevalence of OXA-type carbapenemases among Acinetobacter baumannii strains in a teaching hospital of Tehran

Acta Microbiologica et Immunologica Hungarica

Volumn 64, Issue 4, 2017, Pages 385-394

  Zafari, Mandana ^a   Feizabadi, Mohamad Mehdi ^b,c   Jafari, Sirous ^c   Abdollahi, Alireza ^c   Sabokbar, Azar ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

blaOXA 51 like, blaOXA 58 like, blaOXA 23 like, blaOXA 24 like; CRAB; MDR; Multiplex PCR; XDR

Indexed keywords

AMIKACIN; AMPICILLIN; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DORIPENEM; DOXYCYCLINE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; NETILMICIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULTAMICILLIN; TETRACYCLINE; TICARCILLIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLA OXA 23 LIKE GENE; BLA OXA 24 LIKE GENE; BLA OXA 51 LIKE GENE; BLA OXA 58 LIKE GENE; BROTH DILUTION; CONTROLLED STUDY; ESCHERICHIA COLI; EXTENSIVELY DRUG RESISTANT ACINETOBACTER BAUMANNII; HOSPITAL INFECTION; HOSPITAL PATIENT; IRAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PHENOTYPE; PSEUDOMONAS AERUGINOSA; CLASSIFICATION; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PREVALENCE; STATISTICS AND NUMERICAL DATA; TEACHING HOSPITAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOSPITALS, TEACHING; HUMANS; IRAN; MICROBIAL SENSITIVITY TESTS; PREVALENCE;

EID: 85038618134     PISSN: 12178950     EISSN: 15882640     Source Type: Journal    
DOI: 10.1556/030.64.2017.031     Document Type: Article

References (31)

1. Qureshi, Z. A., Hittle, L. E., O'Hara, J. A., Rivera, J. I., Syed, A., Shields, R. K., Pasculle, A. W., Ernst, R. K., Doi, Y.: Colistin-resistant Acinetobacter baumannii: Beyond carbapenem resistance. Clin Infect Dis 60, 1295-1303 (2015).
2. Maraki, S., Mantadakis, E., Mavromanolaki, V. E., Kofteridis, D. P., Samonis, G.: A 5-year surveillance study on antimicrobial resistance of Acinetobacter baumannii clinical isolates from a Tertiary Greek Hospital. J Infect Chemother 48, 190-198 (2016).
3. Tsakris, A., Ikonomidis, A., Pournaras, S., Tzouvelekis, L. S., Sofianou, D., Legakis, N. J., Maniatis, A. N.: VIM-1 metallo-β-lactamase in Acinetobacter baumannii. Emerg Infect Dis 12, 1-3 (2006).
4. Pogue, J. M., Mann, T., Barber, K. E., Kaye, K. S.: Carbapenem-resistant Acinetobacter baumannii: Epidemiology, surveillance and management. Expert Rev Anti Infect Ther 11, 383-393 (2013).
5. Kim, T., Chong, Y. P., Park, S. Y., Jeon, M. H., Choo, E. J., Chung, J. W., Lee, H. K., Moon, C., Kim, D. M., Peck, K. R., Kim, Y. S.: Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria in critically ill patients: A multicenter study in Korea. Diagn Microbiol Infect Dis 78, 457-461 (2014).
6. Poirel, L., Nordmann, P.: Carbapenem resistance in Acinetobacter baumannii: Mechanisms and epidemiology. Clin Microbiol Infect 12, 826-836 (2006).
7. Nordmann, P., Poirel, L.: Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 8, 321-331 (2002).
8. Woodford, N., Ellington, M. J., Coelho, J. M., Turton, J. F., Ward, M. E., Brown, S., Amyes, S. G., Livermore, D. M.: Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 27, 351-353 (2006).
9. Zanganeh, Z., Eftekhar, F.: Correlation of oxacillinase gene carriage with the genetic fingerprints of imipenem-resistant clinical isolates of Acinetobacter baumannii. Jundishapur J Microbiol 8, 3-5 (2015).
10. Turton, J. F., Woodford, N., Glover, J., Yarde, S., Kaufmann, M. E., Pitt, T. L.: Identification of Acinetobacter baumannii by detection of the bla OXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol 44, 2974-2976 (2006).
11. Paton, R., Miles, R. S., Hood, J., Amyes, S. G., Miles, R. S., Amyes, S. G.: ARI 1: β-lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents 2, 81-87 (1993).
12. Velkov, T., Roberts, K. D., Nation, R. L., Thompson, P. E., Li, J.: Pharmacology of polymyxins: New insights into an 'old' class of antibiotics. Future Microbiol 8, 711-724 (2013).
13. García-Quintanilla, M., Pulido, M. R., Moreno-Martínez, P., Martín-Peña, R., López-Rojas, R., Pachón, J., McConnell, M. J.: Activity of host antimicrobials against multidrug-resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide. Antimicrob Agents Chemother 58, 2972-2975 (2014).
14. Cherkaoui, A., Emonet, S., Renzi, G., Schrenzel, J.: Characteristics of multidrug-resistant Acinetobacter baumannii strains isolated in Geneva during colonization or infection. Ann Clin Microbiol Antimicrob 14, 1-7 (2015).
15. Queenan, A. M., Pillar, C. M., Deane, J., Sahm, D. F., Lynch, A. S., Flamm, R. K., Peterson, J., Davies, T. A.: Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: Results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis 73, 267-270 (2012).
16. Sohail, M., Rashid, A., Aslam, B., Waseem, M., Shahid, M., Akram, M., Khurshid, M., Rasool, M. H.: Antimicrobial susceptibility of Acinetobacter clinical isolates and emerging antibiogram trends for nosocomial infection management. Rev Soc Bras Med Trop 49, 300-304 (2016).
17. Goudarzi, H., Douraghi, M., Ghalavand, Z., Goudarzi, M.: Assessment of antibiotic resistance pattern in Acinetobacter baumannii carrying blaOXA type genes isolated from hospitalized patients. Novel Biomed 1, 54-61 (2013).
18. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial disk diffusion susceptibility tests, 20th Edition. Clinical and Laboratory Standards Institute, Wayne, PA, 2010, p. 29.
19. Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D. L.: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18, 268-281 (2012).
20. Mohajeri, P., Farahani, A., Feizabadi, M. M., Davoodabadi, A., Noroozi, B.: The prevalence of ESBL isolates of Acinetobacter baumannii using pulsed-field gel electrophoresis. Zahedan J Res Med Sci 16, 20-23 (2014).
21. Taherikalani, M., Fatolahzadeh, B., Emaneini, M., Soroush, S., Feizabadi, M. M.: Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran Hospitals. New Microbiol 32, 265-271 (2009).
22. Sheng, W. H., Liao, C. H., Lauderdale, T. L., Ko, W. C., Chen, Y. S., Liu, J. W., Lau, Y. J., Wang, L. S., Liu, K. S., Tsai, T. Y., Lin, S. Y.: A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 14, 764-769 (2010).
23. Lin, M. F., Lan, C. Y.: Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases 2, 787-814 (2014).
24. Lee, S. O., Kim, N. J., Choi, S. H., Kim, T. H., Chung, J. W., Woo, J. H., Ryu, J., Kim, Y. S.: Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: A case-control study. Antimicrob Agents Chemother 48, 224-228 (2004).
25. Higgins, P. G., Dammhayn, C., Hackel, M., Seifert, H.: Global spread of carbapenemresistant Acinetobacter baumannii. J Antimicrob Chemother 65, 233-238 (2010).
26. Ho, P. L., Ho, A. Y., Chow, K. H., Cheng, V. C.: Surveillance for multidrug-resistant Acinetobacter baumannii: A lesson on definitions. Int J Antimicrob Agents 36, 469-471 (2010).
27. Cisneros, J. M., Rodriguez-Bano, J.: Nosocomial bacteremia due to Acinetobacter baumannii: Epidemiology, clinical features and treatment. Clin Microbiol Infect 8, 687-693 (2002).
28. Dalla-Costa, L. M., Coelho, J. M., Souza, H. A., Castro, M. E., Stier, C. J., Bragagnolo, K. L., Rea-Neto, A., Penteado-Filho, S. R., Livermore, D. M., Woodford, N.: Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 41, 3403-3406 (2003).
29. Eser, Ö. K., Ergin, A., Tunçkanat, F., Hasçelik, G.: In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp. New Microbiol 31, 535-542 (2008).
30. Tuon, F. F., Rocha, J. L., Merlini, A. B.: Combined therapy for multi-drug-resistant Acinetobacter baumannii infection - Is there evidence outside the laboratory? J Med Microbiol 64, 951-959 (2015).
31. Vijayakumar, S., Gopi, R., Gunasekaran, P., Bharathy, M., Walia, K., Anandan, S., Veeraraghavan, B.: Molecular characterization of invasive carbapenem-resistant Acinetobacter baumannii from a tertiary care hospital in South India. Infect Dis Ther 5, 379-387 (2016).